BioCentury | Apr 15, 2013
Company News

Inflazyme board of directors update

Inflazyme Pharmaceuticals Ltd. (IZYPF), Vancouver, B.C. Business: Autoimmune/Inflammation Appointed: Jeremy Curnock Cook, director of Rothschild Asset Management Ltd. WIR Staff...
BioCentury | Apr 15, 2013
Company News

Inflazyme board of directors update

Inflazyme Pharmaceuticals Ltd. (IZYPF), Vancouver, B.C. Business: Autoimmune/Inflammation Appointed: Donald Layne, SVP of Research at Toronto General Hospital; Alfred Alberts, retired Merck Research Laboratories executive, who also serves as Chairman of IZYPF's Scientific Advisory Board...
BioCentury | Apr 15, 2013
Company News

Inflazyme management update

Inflazyme Pharmaceuticals Ltd. (IZYPF), Vancouver, B.C. Business: Autoimmune/Inflammation Hired: Michael Liggett, as CFO and secretary; formerly auditor and consultant with Price Waterhouse (Canada) WIR Staff autoimmune Inflammation...
BioCentury | May 31, 2010
Finance

Performance Counts

...pharma: cardiovascular and metabolic disorders Other M&A Target Acquirer Acq value Raised Focus AdProTech Ltd. Inflazyme Pharmaceuticals Ltd....
BioCentury | Dec 8, 2008
Company News

Tripos board of directors update

...Tripos Inc. (TRPS), St. Louis, Mo. Business: Enabling technology Appointed: Alfred Alberts; board member at Inflazyme Pharmaceuticals Ltd....
BioCentury | Aug 25, 2008
Company News

Inflazyme inflammation, neurology news

...by Orexo AB (SSE:ORX, Uppsala, Sweden) (see BioCentury, Oct. 1, 2007, & Dec. 3, 2007). Inflazyme Pharmaceuticals Ltd....
BioCentury | Jul 28, 2008
Clinical News

Helicon, Inflazyme preclinical data

...impairment. Helicon licensed the compound from Inflazyme in 2003. Helicon Therapeutics Inc. , Farmingdale, N.Y. Inflazyme Pharmaceuticals Ltd....
BioCentury | Feb 4, 2008
Product Development

Arius picks its epitope

...the regulation of erythropoiesis, cancer and inflammatory diseases, was discontinued when GlycoDesign was acquired by Inflazyme Pharmaceuticals Ltd....
...Boston, Mass. Genentech Inc. (NYSE:DNA), South San Francisco, Calif. ImmunoGen Inc. (NASDAQ:IMGN), Cambridge, Mass. Inflazyme Pharmaceuticals Ltd....
BioCentury | Jan 7, 2008
Company News

Inflazyme management update

Inflazyme Pharmaceuticals Ltd. (NEX:IZP.H), Richmond, B.C. Business: Inflammation, Neurology Resigned: Kevin Mullane as president and CEO; David Burgoyne as VP of business development; and John Langlands as senior director of clinical research WIR Staff...
BioCentury | Dec 3, 2007
Company News

Biolipox, Inflazyme, Orexo deal

...Nov. 22, the last trading day before the deal closed. Biolipox AB , Stockholm, Sweden Inflazyme Pharmaceuticals Ltd....
Items per page:
1 - 10 of 129
BioCentury | Apr 15, 2013
Company News

Inflazyme board of directors update

Inflazyme Pharmaceuticals Ltd. (IZYPF), Vancouver, B.C. Business: Autoimmune/Inflammation Appointed: Jeremy Curnock Cook, director of Rothschild Asset Management Ltd. WIR Staff...
BioCentury | Apr 15, 2013
Company News

Inflazyme board of directors update

Inflazyme Pharmaceuticals Ltd. (IZYPF), Vancouver, B.C. Business: Autoimmune/Inflammation Appointed: Donald Layne, SVP of Research at Toronto General Hospital; Alfred Alberts, retired Merck Research Laboratories executive, who also serves as Chairman of IZYPF's Scientific Advisory Board...
BioCentury | Apr 15, 2013
Company News

Inflazyme management update

Inflazyme Pharmaceuticals Ltd. (IZYPF), Vancouver, B.C. Business: Autoimmune/Inflammation Hired: Michael Liggett, as CFO and secretary; formerly auditor and consultant with Price Waterhouse (Canada) WIR Staff autoimmune Inflammation...
BioCentury | May 31, 2010
Finance

Performance Counts

...pharma: cardiovascular and metabolic disorders Other M&A Target Acquirer Acq value Raised Focus AdProTech Ltd. Inflazyme Pharmaceuticals Ltd....
BioCentury | Dec 8, 2008
Company News

Tripos board of directors update

...Tripos Inc. (TRPS), St. Louis, Mo. Business: Enabling technology Appointed: Alfred Alberts; board member at Inflazyme Pharmaceuticals Ltd....
BioCentury | Aug 25, 2008
Company News

Inflazyme inflammation, neurology news

...by Orexo AB (SSE:ORX, Uppsala, Sweden) (see BioCentury, Oct. 1, 2007, & Dec. 3, 2007). Inflazyme Pharmaceuticals Ltd....
BioCentury | Jul 28, 2008
Clinical News

Helicon, Inflazyme preclinical data

...impairment. Helicon licensed the compound from Inflazyme in 2003. Helicon Therapeutics Inc. , Farmingdale, N.Y. Inflazyme Pharmaceuticals Ltd....
BioCentury | Feb 4, 2008
Product Development

Arius picks its epitope

...the regulation of erythropoiesis, cancer and inflammatory diseases, was discontinued when GlycoDesign was acquired by Inflazyme Pharmaceuticals Ltd....
...Boston, Mass. Genentech Inc. (NYSE:DNA), South San Francisco, Calif. ImmunoGen Inc. (NASDAQ:IMGN), Cambridge, Mass. Inflazyme Pharmaceuticals Ltd....
BioCentury | Jan 7, 2008
Company News

Inflazyme management update

Inflazyme Pharmaceuticals Ltd. (NEX:IZP.H), Richmond, B.C. Business: Inflammation, Neurology Resigned: Kevin Mullane as president and CEO; David Burgoyne as VP of business development; and John Langlands as senior director of clinical research WIR Staff...
BioCentury | Dec 3, 2007
Company News

Biolipox, Inflazyme, Orexo deal

...Nov. 22, the last trading day before the deal closed. Biolipox AB , Stockholm, Sweden Inflazyme Pharmaceuticals Ltd....
Items per page:
1 - 10 of 129